Eton Pharmaceuticals Inc (ETON)
Eton Pharmaceuticals Inc. is a NASDAQ-listed common stock issuer in the healthcare sector focused on pharmaceuticals. The company develops and commercializes medicines for rare diseases and markets several approved products, including treatments used for severe primary IGF-1 deficiency, adrenal insufficiency, adrenocortical insufficiency, Wilson disease, phenylketonuria, N-acetylglutamate synthase deficiency, homocystinuria, and tyrosinemia type 1. Eton also has a pipeline of late-stage product candidates such as ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector. Incorporated in 2017, the company is based in Deer Park, Illinois.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ETON
|
$37.57
|
-11.8% Downside
|
Fair
|
$49.25
|
15.6% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-791.1x
|
38.1x
|
13.4x
|
1.125 B
|
1.179 B
|
2.7%
|
76.8%
|
9.4
|
—
|
-1,046.2%
|
